BE2017C027I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C027I2
BE2017C027I2 BE2017C027C BE2017C027C BE2017C027I2 BE 2017C027 I2 BE2017C027 I2 BE 2017C027I2 BE 2017C027 C BE2017C027 C BE 2017C027C BE 2017C027 C BE2017C027 C BE 2017C027C BE 2017C027 I2 BE2017C027 I2 BE 2017C027I2
Authority
BE
Belgium
Application number
BE2017C027C
Other languages
French (fr)
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of BE2017C027I2 publication Critical patent/BE2017C027I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • A61K49/1812Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BE2017C027C 2004-05-03 2017-07-10 BE2017C027I2 (pm)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56792104P 2004-05-03 2004-05-03
US11/601,451 US8658203B2 (en) 2004-05-03 2006-11-17 Liposomes useful for drug delivery to the brain

Publications (1)

Publication Number Publication Date
BE2017C027I2 true BE2017C027I2 (pm) 2024-08-08

Family

ID=46045566

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C027C BE2017C027I2 (pm) 2004-05-03 2017-07-10

Country Status (2)

Country Link
US (3) US8658203B2 (pm)
BE (1) BE2017C027I2 (pm)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
ES2616047T3 (es) 2004-05-03 2017-06-09 Merrimack Pharmaceuticals, Inc. Liposomas útiles para la administración de fármacos
GEP20094620B (en) * 2004-06-01 2009-02-25 Yakult Honsha Kk Irinotecan preparation
WO2006042090A1 (en) 2004-10-05 2006-04-20 Avigen, Inc. Stepped cannula
JP5238503B2 (ja) 2005-08-23 2013-07-17 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 対流増加送達を用いた治療薬の慢性的な送達のための逆流防止カニューレ及びシステム
US20140335166A1 (en) * 2013-05-08 2014-11-13 Michael W. Fountain Methods of Making and Using Nano Scale Particles
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
WO2009033176A1 (en) * 2007-09-07 2009-03-12 The Trustees Of The University Of Pennsylvania A method of targeting a transferrin receptor
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR IMPROVING INFLAMMATION OF SN, PSYCHOSIS, DELI, PTSD OR PTSD
US20100284912A1 (en) * 2007-12-04 2010-11-11 Bracco Diagnostics Inc. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
JP5588619B2 (ja) * 2009-03-11 2014-09-10 一丸ファルコス株式会社 pH応答性リポソーム
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
WO2011130107A2 (en) 2010-04-16 2011-10-20 Surgivision, Inc. Mri surgical systems including mri-compatible surgical cannulae for transferring a substance to and/or from a patient
CN107261110A (zh) * 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
CN104523565A (zh) * 2010-11-26 2015-04-22 约翰内斯堡威特沃特斯兰德大学 用于治疗精神分裂症的可植入头颅中的装置
US10980798B2 (en) * 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
AU2013221615B2 (en) 2012-02-14 2018-02-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
EP2892509B1 (en) * 2012-09-04 2024-12-11 Lauren Sciences LLC Bolaamphiphilic compounds, compositions and uses thereof
US20150306236A1 (en) * 2012-09-04 2015-10-29 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
US20140205543A1 (en) * 2013-01-24 2014-07-24 Memorial Sloan-Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
CA2899882C (en) 2013-02-01 2023-12-12 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into liposomes
US9289502B2 (en) 2013-03-08 2016-03-22 Emerald Therapeutics, Inc. Preparation of oligo conjugates
US20140329889A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
US20170182129A1 (en) 2014-04-03 2017-06-29 The Regents Of The University Of California Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure
CN106999419A (zh) 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 远程装载略微水溶性药物至脂质膜泡
US20160158154A1 (en) * 2014-12-05 2016-06-09 Georgia Tech Research Corporation Protein vesicles and methods of making and using thereof
EP3229802A1 (en) * 2014-12-09 2017-10-18 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR20180037210A (ko) 2015-08-20 2018-04-11 입센 바이오팜 리미티드 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법
US11260126B2 (en) * 2015-08-21 2022-03-01 University Of Otago Acoustic driven drug delivery systems
SG10201913077QA (en) 2015-08-21 2020-02-27 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
CA3001467A1 (en) * 2015-10-16 2017-04-20 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
WO2017100125A1 (en) 2015-12-10 2017-06-15 The Regents Of The University Of California Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
WO2017142698A1 (en) 2016-02-17 2017-08-24 MRI Interventions, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
US11071726B2 (en) 2016-11-02 2021-07-27 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
WO2019016240A1 (en) 2017-07-19 2019-01-24 Leadiant Biosciences Ltd ADENOSINE DEAMINASE FOR TREATING OR IMPROVING SCLERRODERMIS ASSOCIATED VASCULOPATHY
RU2744016C1 (ru) 2017-08-09 2021-03-02 ЗедТиИ КОРПОРЕЙШН Реализации качества обслуживания для отделения плоскости пользователя
JP6297737B1 (ja) * 2017-09-25 2018-03-20 ジェイ−ネットワーク,インコーポレイテッド 正に帯電した荷電ニオソームの調製方法及び荷電ニオソーム
US20210113595A1 (en) * 2018-04-30 2021-04-22 Purdue Research Foundation Liposomal nano formulation of combinational antibiotics and the uses thereof
EP3781074A1 (en) 2018-05-09 2021-02-24 ClearPoint Neuro, Inc. Mri compatible intrabody fluid transfer systems and related devices and methods
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
DK3599243T3 (da) 2018-07-26 2023-07-10 Cvie Therapeutics Ltd 17beta-heterocyklyl-digitalis-lignende forbindelser til behandlingen af hjertesvigt
CN113056259A (zh) * 2018-11-14 2021-06-29 台湾微脂体股份有限公司 包含用于治疗因骨密度降低或软骨损失导致的疾病的治疗剂的缓释药物组合物及其用途
NZ778977A (en) 2019-02-18 2025-06-27 Lilly Co Eli Therapeutic antibody formulation
BR112021017009A2 (pt) 2019-03-05 2021-11-09 Windtree Therapeutics Inc Formulação intravenosa contendo istaroxima para o tratamento da insuficiência cardíaca aguda (ahf)
WO2021022088A1 (en) * 2019-08-01 2021-02-04 Incube Labs, Llc Intracranial delivery of medicinal solution
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
FI3805243T3 (fi) 2019-10-09 2024-02-07 Windtree Therapeutics Inc Androstaanijohdannaisia, joilla on aktiivisuus puhtaina tai pääasiallisesti puhtaina SERCA2a:n stimulaattoreina, sydämen vajaatoiminnan hoitoon
AU2021342431A1 (en) * 2020-09-16 2023-07-13 Imagion Biosystems, Inc. Methods and apparatuses for the synthesis of drug-loaded magnetic micelle aggregates
EP4284519A4 (en) 2021-02-01 2024-12-25 The Regents of the University of California METHODS FOR TREATING AND ALLEVIATING CANCER
IL305955A (en) 2021-03-18 2023-11-01 Univ California Preparations and methods for targeting inflammatory or active cells and treating or improving inflammatory conditions and pain
CN115364218A (zh) * 2021-05-21 2022-11-22 杭州高田生物医药有限公司 一种特定药脂比的药物组合物在抗肿瘤中的应用
WO2023004113A2 (en) 2021-07-22 2023-01-26 The Regents Of The University Of California Compositions and methods for using purified human rna editing enzymes
US20250122193A1 (en) * 2021-12-22 2025-04-17 Mycural Therapeutics Novel pyridocarbazolium compounds and medical uses thereof
CN116731010B (zh) * 2023-06-08 2025-02-11 西南大学 长春胺类衍生物及其制备方法和应用
CN116874540A (zh) * 2023-07-20 2023-10-13 上海灵瑞医药有限公司 硫酸酯三乙铵盐的合成方法
WO2025076208A1 (en) 2023-10-03 2025-04-10 Raft Pharmaceuticals, Inc. Compositions and methods for treating pain disorders
CN119909018B (zh) * 2025-04-01 2025-09-02 山东新时代药业有限公司 一种注射用氟维司群长效脂质体及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578987A (en) * 1897-03-16 Mechanism for propelling vessels
DE2740053A1 (de) 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
US4192869A (en) 1977-09-06 1980-03-11 Studiengesellschaft Kohle Mbh. Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles
US4397846A (en) 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4649155A (en) 1983-07-22 1987-03-10 Hoffmann-La Roche Inc. Injectable solutions
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
PL296382A1 (en) 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
CA2111593A1 (en) 1991-07-03 1993-01-21 Eric A. Forssen Loading technique for preparing drug containing liposomes
US5281237A (en) 1992-09-25 1994-01-25 Gimpelson Richard J Surgical stitching device and method of use
US6350853B1 (en) * 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4320597A1 (de) 1993-06-22 1995-01-05 Heinz C Prof Dr Dr Schroeder Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren
US6743917B2 (en) 1993-06-30 2004-06-01 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
FI963065L (fi) * 1994-02-04 1996-09-30 Scotia Lipidteknik Ab Kaksikerroksiset valmisteet
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
WO1996025147A1 (en) 1995-02-14 1996-08-22 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US6417326B1 (en) 1996-04-11 2002-07-09 The University Of British Columbia Fusogenic liposomes
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6110491A (en) 1996-10-22 2000-08-29 Hermes Biosciences, Inc. Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
AU8285998A (en) 1997-07-02 1999-01-25 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
US6316612B1 (en) 1997-08-22 2001-11-13 Ribozyme Pharmaceuticals, Inc. Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
US6083923A (en) 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
RU2130771C1 (ru) 1998-06-01 1999-05-27 Автушенко Сергей Сергеевич Способ получения липосомальных препаратов
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
AU1678900A (en) 1998-08-11 2000-03-06 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
US6162462A (en) 1998-08-12 2000-12-19 New York University Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
KR100679906B1 (ko) 1998-09-16 2007-02-07 알자 코포레이션 리포솜-엔트랩된 토포이소머라제 억제제
US6291676B1 (en) 1999-03-03 2001-09-18 University Of Kentucky Research Foundation Water-soluble derivatives of camptothecin/homocamptothecin
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
CN1172670C (zh) 1999-04-29 2004-10-27 阿尔萨公司 用于改善药物保留的脂质体组合物
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
ES2272496T3 (es) 2000-02-04 2007-05-01 Lipoxen Technologies Limited Procedimiento de deshidratacion/rehidritacion para la preparacion de lipososmas.
AU2001261473B2 (en) 2000-05-15 2006-09-14 Board Of Trustees Of The University Of Arkansas Compositions and methods for the treatment of colorectal cancer
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
EP1341497A4 (en) 2000-11-02 2005-10-19 Smithkline Beecham Corp RECEPTOR-LIPID ANTAGONIST CONJUGATES AND DELIVERY VEHICLES CONTAINING THE SAME
MXPA03008864A (es) 2001-03-26 2004-12-06 Johnson & Johnson Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico.
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
TWI235066B (en) 2001-10-03 2005-07-01 Celator Technologies Inc Liposome loading with metal ions
US20030129224A1 (en) 2001-11-13 2003-07-10 Paul Tardi Lipid carrier compositions and methods for improved drug retention
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
AU2003231157C1 (en) 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
DK1519714T3 (da) 2002-06-28 2011-01-31 Protiva Biotherapeutics Inc Fremgangsmåde og apparat til fremstilling af liposomer
US20040243101A1 (en) * 2002-07-02 2004-12-02 Gillis Edward M. Minimally invasive drug delivery catheter
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
CA2506749A1 (en) 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
EP1643972A4 (en) 2003-06-27 2010-01-20 Smithkline Beecham Corp STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
EP1648299A4 (en) 2003-07-09 2008-10-22 California Pacific Med Center REMOTE DETERMINATION OF THE DELIVERY OF SUBSTANCES IN CELLS
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
ES2616047T3 (es) 2004-05-03 2017-06-09 Merrimack Pharmaceuticals, Inc. Liposomas útiles para la administración de fármacos
WO2006042090A1 (en) 2004-10-05 2006-04-20 Avigen, Inc. Stepped cannula
US20060129126A1 (en) * 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
RU2438696C2 (ru) * 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей

Also Published As

Publication number Publication date
US20140127136A1 (en) 2014-05-08
US8658203B2 (en) 2014-02-25
US20070110798A1 (en) 2007-05-17
US20170035749A1 (en) 2017-02-09
US9737528B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
BE2024C508I2 (pm)
BE2022C549I2 (pm)
BE2023C542I2 (pm)
BE2021C001I2 (pm)
BE2020C513I2 (pm)
BE2020C517I2 (pm)
BE2019C540I2 (pm)
BE2019C523I2 (pm)
BE2019C548I2 (pm)
BE2019C506I2 (pm)
BE2018C045I2 (pm)
BE2020C525I2 (pm)
BE2017C063I2 (pm)
BE2017C027I2 (pm)
BE2017C023I2 (pm)
BE2017C002I2 (pm)
BE2016C067I2 (pm)
BE2016C014I2 (pm)
BE2015C041I2 (pm)
BE2015C066I2 (pm)
BE2014C071I2 (pm)
BE2014C064I2 (pm)
BE2014C063I2 (pm)
BE2014C010I2 (pm)
BE2013C071I2 (pm)